@article {10753, title = {Afebrile seizures in infants: Never forget magnesium!}, journal = {J Paediatr Child Health}, volume = {54}, year = {2018}, month = {2018 Apr}, pages = {446-448}, issn = {1440-1754}, doi = {10.1111/jpc.13854}, author = {Minute, Marta and Ventura, Giovanna and Giorgi, Rita and Faletra, Flavio and Costa, Paola and Cozzi, Giorgio} } @article {8509, title = {A Child with Severe Developmental Delay and Growth Retardation.}, journal = {J Pediatr}, volume = {175}, year = {2016}, month = {2016 Aug}, pages = {241-241.e1}, issn = {1097-6833}, doi = {10.1016/j.jpeds.2016.05.006}, author = {Rossetto, Elena and Matarazzo, Lorenza and Maschio, Massimo and Taddio, Andrea and Costa, Paola and Ventura, Alessandro} } @article {8508, title = {Efficacy of ketamine in refractory convulsive status epilepticus in children: a protocol for a sequential design, multicentre, randomised, controlled, open-label, non-profit trial (KETASER01).}, journal = {BMJ Open}, volume = {6}, year = {2016}, month = {2016}, pages = {e011565}, abstract = {

INTRODUCTION: Status epilepticus (SE) is a life-threatening neurological emergency. SE lasting longer than 120 min and not responding to first-line and second-line antiepileptic drugs is defined as {\textquoteright}refractory{\textquoteright} (RCSE) and requires intensive care unit treatment. There is currently neither evidence nor consensus to guide either the optimal choice of therapy or treatment goals for RCSE, which is generally treated with coma induction using conventional anaesthetics (high dose midazolam, thiopental and/or propofol). Increasing evidence indicates that ketamine (KE), a strong N-methyl-d-aspartate glutamate receptor antagonist, may be effective in treating RCSE. We hypothesised that intravenous KE is more efficacious and safer than conventional anaesthetics in treating RCSE.

METHODS AND ANALYSIS: A multicentre, randomised, controlled, open-label, non-profit, sequentially designed study will be conducted to assess the efficacy of KE compared with conventional anaesthetics in the treatment of RCSE in children. 10 Italian centres/hospitals are involved in enrolling 57 patients aged 1 month to 18 years with RCSE. Primary outcome is the resolution of SE up to 24 hours after withdrawal of therapy and is updated for each patient treated according to the sequential method.

ETHICS AND DISSEMINATION: The study received ethical approval from the Tuscan Paediatric Ethics Committee (12/2015). The results of this study will be published in peer-reviewed journals and presented at international conferences.

TRIAL REGISTRATION NUMBER: NCT02431663; Pre-results.

}, issn = {2044-6055}, doi = {10.1136/bmjopen-2016-011565}, author = {Rosati, Anna and Ilvento, Lucrezia and L{\textquoteright}Erario, Manuela and De Masi, Salvatore and Biggeri, Annibale and Fabbro, Giancarlo and Bianchi, Roberto and Stoppa, Francesca and Fusco, Lucia and Pulitan{\`o}, Silvia and Battaglia, Domenica and Pettenazzo, Andrea and Sartori, Stefano and Biban, Paolo and Fontana, Elena and Cesaroni, Elisabetta and Mora, Donatella and Costa, Paola and Meleleo, Rosanna and Vittorini, Roberta and Conio, Alessandra and Wolfler, Andrea and Mastrangelo, Massimo and Mondardini, Maria Cristina and Franzoni, Emilio and McGreevy, Kathleen S and Di Simone, Lorena and Pugi, Alessandra and Mirabile, Lorenzo and Vigevano, Federico and Guerrini, Renzo} } @article {8033, title = {Diagnostic criteria currently proposed for "ictal epileptic headache": Perspectives on strengths, weaknesses and pitfalls.}, journal = {Seizure}, volume = {31}, year = {2015}, month = {2015 Sep}, pages = {56-63}, abstract = {

PURPOSE: When we published the diagnostic criteria for "ictal epileptic headache" in 2012, we deliberately and consciously chose to adopt restrictive criteria that probably underestimate the phenomenon, rather than spread panic among patients and physicians who are reluctant to accept this entity.

METHODS: Here we discuss four intriguing clinical cases to highlight why we believe, to this day, that it is necessary to follow these restrictive diagnostic criteria.

CONCLUSIONS: EEG is not recommended as a routine examination for children diagnosed with headache, but it is mandatory and must be carried out promptly in cases of prolonged headache that does not respond to antimigraine drugs, if epilepsy is suspected or has been diagnosed previously. This is not a marginal or irrelevant question because possible isolated, non-motor, ictal manifestations should be taken into account before declaring that an epileptic patient is "seizure free" so as to ensure that any decision taken to suspend anticonvulsant therapy is safe.

}, issn = {1532-2688}, doi = {10.1016/j.seizure.2015.07.005}, author = {Parisi, Pasquale and Verrotti, Alberto and Costa, Paola and Striano, Pasquale and Zanus, Caterina and Carrozzi, Marco and Raucci, Umberto and Villa, Maria Pia and Belcastro, Vincenzo} } @article {3613, title = {Long-term follow-up in children with benign convulsions associated with gastroenteritis.}, journal = {Eur J Paediatr Neurol}, volume = {18}, year = {2014}, month = {2014 Sep}, pages = {572-7}, abstract = {

BACKGROUND: The outcome of benign convulsions associated with gastroenteritis (CwG) has generally been reported as being excellent. However, these data need to be confirmed in studies with longer follow-up evaluations.

AIM: To assess the long-term neurological outcome of a large sample of children presenting with CwG.

METHODS: We reviewed clinical features of 81 subjects presenting with CwG (1994-2010) from three different Italian centers with a follow-up period of at least 3 years.

RESULTS: Follow-up period ranged from 39 months to 15 years (mean 9.8 years). Neurological examination and cognitive level at the last evaluation were normal in all the patients. A mild attention deficit was detected in three cases (3.7\%). Fourteen children (17.3\%) received chronic anti-epileptic therapy. Interictal EEG abnormalities detected at onset in 20 patients (24.7\%) reverted to normal. Transient EEG epileptiform abnormalities were detected in other three cases (3.7\%), and a transient photosensitivity in one (1.2\%). No recurrence of CwG was observed. Three patients (3.7\%) presented with a febrile seizure and two (2.5\%) with an unprovoked seizure, but none developed epilepsy.

CONCLUSIONS: The long-term evaluation of children with CwG confirms the excellent prognosis of this condition, with normal psychomotor development and low risk of relapse and of subsequent epilepsy.

}, keywords = {Adolescent, Anticonvulsants, Attention Deficit Disorder with Hyperactivity, Child, Child, Preschool, Electroencephalography, Epilepsy, Female, Gastroenteritis, Humans, Longitudinal Studies, Male, Neurologic Examination, Retrospective Studies}, issn = {1532-2130}, doi = {10.1016/j.ejpn.2014.04.006}, author = {Verrotti, Alberto and Moavero, Romina and Vigevano, Federico and Cantonetti, Laura and Guerra, Azzurra and Spezia, Elisabetta and Tricarico, Antonella and Nanni, Giuliana and Agostinelli, Sergio and Chiarelli, Francesco and Parisi, Pasquale and Capovilla, Giuseppe and Beccaria, Francesca and Spalice, Alberto and Coppola, Giangennaro and Franzoni, Emilio and Gentile, Valentina and Casellato, Susanna and Veggiotti, Pierangelo and Malgesini, Sara and Crichiutti, Giovanni and Balestri, Paolo and Grosso, Salvatore and Zamponi, Nelia and Incorpora, Gemma and Savasta, Salvatore and Costa, Paola and Pruna, Dario and Cusmai, Raffaella} } @article {1908, title = {Involuntary movements after correction of vitamin B12 deficiency: a video-case report.}, journal = {Epileptic Disord}, volume = {14}, year = {2012}, month = {2012 Jun}, pages = {174-80}, abstract = {

Involuntary movements can appear before and after initiation of vitamin B12 treatment. The pathogenesis of involuntary movements in vitamin B12 deficiency and their relationship with cobalamin injection remain unclear due to a lack of video-EEG documentation making the electroclinical correlation difficult to ascertain. Here, we report video-EEG and neuroimaging findings of an 11-month-old girl with vitamin B12 deficiency, who acutely developed involuntary movements a few days after initiation of vitamin B12 treatment with normal vitamin plasmatic levels. Abnormal movements were a combination of tremor and myoclonus involving the face, mouth, and left arm, which disappeared after discontinuation of therapy. [Published with video sequences].

}, keywords = {Atrophy, Brain, Dyskinesias, Electroencephalography, Female, Humans, Infant, Magnetic Resonance Imaging, Myelin Sheath, Myoclonus, Tremor, Video Recording, Vitamin B 12, Vitamin B 12 Deficiency, Vitamins}, issn = {1294-9361}, doi = {10.1684/epd.2012.0507}, author = {Zanus, Caterina and Alberini, Elena and Costa, Paola and Colonna, Franco and Zennaro, Floriana and Carrozzi, Marco} } @article {1609, title = {A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy.}, journal = {Epilepsia}, volume = {52}, year = {2011}, month = {2011 Apr}, pages = {802-9}, abstract = {

PURPOSE: To evaluate the potential efficacy of levetiracetam as an antiabsence agent in children and adolescents with newly diagnosed childhood or juvenile absence epilepsy.

METHODS: Patients were randomized in a 2:1 ratio to receive de novo monotherapy with levetiracetam (up to 30 mg/kg/day) or placebo for 2 weeks under double-blind conditions. Responder status (primary end point) was defined as freedom from clinical seizures on days 13 and 14 and from electroencephalographic (EEG) seizures during a standard EEG recording with hyperventilation and intermittent photic stimulation on day 14. The double-blind phase was followed by an open-label follow-up.

KEY FINDINGS: Nine of 38 patients (23.7\%) were responders in the levetiracetam group, compared with one of 21 (4.8\%) in the placebo group (p = 0.08). Seven of 38 patients (18.4\%) were free from clinical and EEG seizures during the last 4 days of the trial (including 24-h EEG monitoring on day 14) compared with none of the patients treated with placebo (p = 0.04). Seventeen patients remained seizure-free on levetiracetam after 1 year follow-up. Of the 41 patients who discontinued levetiracetam due to lack of efficacy (n = 39) or adverse events (n = 2), 34 became seizure-free on other treatments.

SIGNIFICANCE: Although superiority to placebo just failed to reach statistical significance for the primary end point, the overall findings are consistent with levetiracetam having modest efficacy against absence seizures. Further controlled trials exploring larger doses and an active comparator are required to determine the role of levetiracetam in the treatment of absence epilepsy.

}, keywords = {Adolescent, Age Factors, Anticonvulsants, Child, Child, Preschool, Double-Blind Method, Drug Resistance, Epilepsy, Absence, Female, Humans, Male, Outcome Assessment (Health Care), Piracetam}, issn = {1528-1167}, doi = {10.1111/j.1528-1167.2010.02976.x}, author = {Fattore, Cinzia and Boniver, Clementina and Capovilla, Giuseppe and Cerminara, Caterina and Citterio, Antonietta and Coppola, Giangennaro and Costa, Paola and Darra, Francesca and Vecchi, Marilena and Perucca, Emilio} }